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Abstract
With great advancements in the therapeutic modalities used for the treatment of chronic liver diseases, the
accurate assessment of liver fibrosis is a vital need for successful individualized management of disease activity in
patients. The lack of accurate, reproducible and easily applied methods for fibrosis assessment has been the major
limitation in both the clinical management and for research in liver diseases. However, the problem of the
development of biomarkers capable of non-invasive staging of fibrosis in the liver is difficult due to the fact that
the process of fibrogenesis is a component of the normal healing response to injury, invasion by pathogens, and
many other etiologic factors. Current non-invasive methods range from serum biomarker assays to advanced
imaging techniques such as transient elastography and magnetic resonance imaging (MRI). Among non-invasive
methods that gain strongest clinical foothold are FibroScan elastometry and serum-based APRI and FibroTest.
There are many other tests that are not yet widely validated, but are none the less, promising. The rate of
adoption of non-invasive diagnostic tests for liver fibrosis differs from country to country, but remains limited. At
the present time, use of non-invasive procedures could be recommended as pre-screening that may allow
physicians to narrow down the patients’ population before definitive testing of liver fibrosis by biopsy of the liver.
This review provides a systematic overview of these techniques, as well as both direct and indirect biomarkers
based approaches used to stage fibrosis and covers recent developments in this rapidly advancing area.
Review
Liver fibrosis is defined as the building up of excessive
amount of extracellular matrix, also known as scar tis-
sue, in the liver parenchyma. While reviewing fibrosis as
a component of the pathogenesis of a disease, it is
important to remember that the process of fibrogenesis
is also a component of the normal healing response to
various kinds of injury. In the liver, this healing process
normally involves the recruitment of immune and/or
inflammatory cells to the site of injury, secretion of
extracellular matrix (ECM) proteins, reorganization of
the ECM and possible regeneration of the hepatic tissue.
When the damage to the liver is chronic, excess fibrous
connective tissue accumulates. In time, this process
eventually distorts the normal parenchymal structure of
the liver and impairs its function. As chronic liver dis-
ease progresses, hepatic fibrosis is accompanied by the
formation of septae and nodules that intervene with the
portal blood flow, leading to hypertension and formation
of distinctive cirrhotic architecture. At all stages of the
fibrogenesis, the stress exerted on the liver parenchyma
is exemplified by subsequent activation of the immune
system accompanied by increased levels of certain cyto-
kines and growth factors, which augment fibrogenesis.
In proinflammatory fibrotic microenvironment, constant
stimulation of hepatocellular regeneration could predis-
pose to the development of hepatocellular carcinoma
(HCC). However disruptive, hepatic fibrosis even early
cirrhosis can be reversed by suppression of the fibrotic
response [1,2].
The Biology of Liver Fibrosis
The most important cellular player in the production of
the extracellular matrix is the myofibroblast (MF). A
wide array of cells of different origins can be converted
into fibrogenic MFs, including portal MFs and bone
marrow-derived mesenchymal stem cells. Some epithe-
lial cells including hepatocytes and biliary epithelial cells
(cholangiocytes) could be activated to function as myofi-
broblasts through the process of Epithelial-Mesenchymal
Transition (EMT) [3]. However, the predominant MF-
producing liver cells are quiescent hepatic stellate cells
(HSC), also known as Ito cells or perisinusoidal cells
residing in the space of Disse and storing retinoids [4].
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fibrogenesis. For example, hepatocytes can respond to
this damage in multiple ways, including production of
reactive oxygen species (ROS) and apoptosis, while the
resident liver macrophages called Kupffer cells elicit a
massive immune response resulting in the recruitment
of other inflammatory cells to the site of injury [5].
Attracted to the chemokines produced by the Kupffer
cells, the leukocytes exit out of the vasculature towards
the injury site and contribute to the release of additional
pro-inflammatory and pro-fibrotic mediators, including
cytokines such as tumor necrosis factor alpha (TNF-a)
and various interleukins. Reactive oxygen and nitrogen
species, proteases, and lipid metabolites such as prosta-
glandins and thromboxane are also released [6]. As a
result of this response, quiescent HSCs are converted to
activated myofibroblasts [7] and, in turn, contribute to
the chemotaxis of leukocytes as well as their own che-
motaxis through the production of chemokines and
cytokines such as monocyte chemotactic protein-1
(MCP-1) [8]. As a result, activated HSCs start expres-
sing the Platelet Derived Growth Factor (PDGF) recep-
tor and Transforming Growth Factor (TGF) receptor.
TGF-b is the central mediator of fibrogenesis, while
PGDF stimulates proliferation of the HSCs. Activation
of HSCs is associated with a gradual replacement of the
basement membrane-like extracellular matrix (ECM)
within the space of Disse by the collagen rich fibers [7]
and the production of fibrous bands [8]. In advanced
stages of fibrosis, the liver contains approximately six
times more ECM components than normal, including
collagens (I, III, and IV), fibronectin, undulin, elastin,
laminin, hyaluronan, and proteoglycans [8].
A sc a nb es u r m i s e df r o me x i s t i n ge v i d e n c e ,an u m b e r
of functionally diverse biomolecules could be developed
as biomarkers for hepatic fibrosis. One can look for bio-
markers among molecules that change expression in the
process of HSC activation or at the methods that enu-
merate MFs or their products. Another approach can
look at direct quantification of ECM within the liver, or
the particular molecules involved in the process of profi-
brogenic inflammation within the liver parenchyma. For
any of these biomarkers, the clinical utility in the setting
of the liver disease cannot be derived from the function-
ality of the respective molecules, thus, emphasizing the
importance of extensive validation. Moreover, as the
types of liver fibrosis differ in the fibrogenic mechanisms
and in the distribution of the damage within the liver,
each biomarker or panel thereof should be evaluated
across a variety of clinical cohorts.
Types and Causes of Acquired Liver Fibrosis
Acquired fibrosis may result from the action of a num-
ber of pathogenic factors and toxic exposures such as
long-term excessive alcohol consumption, cholestasis,
autoimmune liver diseases, iron or copper overload,
chronic viral hepatitis or the presence of non-alcoholic
fatty liver disease (NAFLD). These etiological factors
may work separately or in combination with each other
to produce cumulative effects. In this review, we will
discuss the types of damage associated with the most
common causes of acquired hepatic fibrosis and the bio-
markers being developed in order to quantify and stage
them. It is important to note that the presence of fibro-
tic changes and even significant fibrosis in different etio-
logical contexts has different clinical meanings. For
example, in the case of hepatitis C the presence of fibro-
tic changes could argue for the need for antiviral treat-
ment, while in the case of NAFLD it does not change
the therapeutic options, but may provide important
prognostic information.
Alcoholic Liver Disease
Excessive and chronic alcohol consumption is an impor-
tant causal factor of liver fibrosis and cirrhosis. The pro-
cess of the breakdown of ethanol produces two pro-
fibrotic agents, acetaldehyde and reactive oxygen species
(ROS). In hepatocytes, the primary site for alcohol meta-
bolism, acetaldehyde and ROS are produced in abun-
dance, then they diffuse outside and enter HSCs.
Acetaldehyde directly up-regulates the transcription of
collagen I [9] and the synthesis of transforming growth
factor-beta 1 (TGF-b1 ) .E x p o s u r et oR O Ss e n s i t i z e s
HSCs to various pro-inflammatory factors and elicits the
production of inflammatory mediators that contribute to
the fibrotic changes in the liver [10]. In ALD, the fibro-
tic changes in the liver start in the pericentral and peri-
sinusoidal areas [9,10].
Non-alcoholic Fatty Liver Diseases (NAFLD)
NAFLD and its subtype, Non-Alcoholic Steatohepatitis,
or NASH, are usually seen in individuals with metabolic
syndrome (MS) or its components such as obesity, type-
2 diabetes (DM), dyslipidemia, and insulin resistance.
NASH rarely manifests as inflammation and/or apopto-
sis/necrosis only, more often than not it is also accom-
panied by liver fibrosis. To date, the pathogenesis of
NASH-related liver fibrosis is not entirely well under-
stood [8]. Evidence provided by numerous studies links
obesity, insulin resistance and the progression of fibrosis
together in one vicious circle [11]. The same factors are
also known for their association with hepatic fibrosis.
For example, leptin, the well-know adipokine produced
proportionally to the mass of the visceral adipose com-
partment, also augments fibrogenesis by stimulating
phagocytic activity and cytokine secretion by Kupffer
cells and macrophages [12] as well as the proliferative
and ROS generating activities of the endothelial cells
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tory actions in HSC by increasing the expression of
both MCP-1 and interleukin-8 (IL-8) as well as activat-
ing the transcription factor, NFkB [14]. From examples
mentioned above, one can derive that the initial stages
of the pathogenesis of liver fibrosis associated with
NAFLD depends primarily on the soluble factors pro-
duced by excessive visceral adipose and on a skewed
distribution of the soluble fat particles in the
bloodstream.
Cholestatic Liver Diseases
Cholestasis (reduced bile duct excretion) is another well-
known cause of liver fibrosis. Cholestasis triggers the
proliferation of the cholangiocyte lining of the intrahe-
patic and extrahepatic bile duct systems through a com-
plex regulatory milieu that involves both autocrine and
paracrine factors [15]. The activation of biliary prolifera-
tion is known as ductular reaction. Proliferating bile
duct epithelial cells produce the profibrogenic connec-
tive tissue growth factor (CTGF) that stimulates myofi-
broblast generation through EMT and collagen
deposition [16]. The primary players in the fibrotic reac-
tion to cholestasis are the inflammatory responses pro-
pagated by neutrophils and resulting from this oxidative
stress. The fibrotic reaction is initiated in the portal area
of the liver normally enriched in fibroblasts available for
MF conversion [9,10]. The layer of hepatocytes adjacent
to these fibroblasts is liable to immediate destruction
leading to the enlargement of the portal field and rapid
activation of the portal fibroblasts [10].
Chronic Viral Hepatitis
Chronic viral infections such as hepatitis B (HBV) or
hepatitis C (HCV) viruses pose an important risk for the
development of liver fibrosis. The general mechanism of
the fibrogenesis in chronic viral hepatitis is less clear
than that in non-viral chronic diseases. In chronic viral
hepatitis, fibrosis is usually initiated in the portal area
[9]. Most likely, the pathogenesis is multifactorial as it
involves a combination of both viral and host-specific
factors, including oxidative stress, hepatic steatosis,
increased iron stores, and increased rate of hepatocyte
apoptosis, under the pressure of the viral proteins and
viral replication.
In chronic HCV infection, the viral core, NS5 and NS3
proteins have been demonstrated to initiate a cascade of
molecular events that can eventually lead to fibrosis.
HCV proteins appear to affect both lipid accumulation
and degradation, with the consequent disruption of the
normal process of lipid compartmentalization and meta-
bolism, skewing towards ROS production. In the case of
HBV infection, studies have shown that the X protein of
HBV (HBx) directly induces TGF-b secretion by
hepatocytes and, thus, contributes to the paracrine acti-
vation of HSC’s [17]. Both HIV-HBV and HIV-HCV co-
infected patients are at increased risk for progression of
their liver disease as compared to patients who are
mono-infected with HCV or HBV [18].
Diagnostics of Acquired Liver Fibrosis
With the advancements in the treatment of patients
with chronic liver diseases, the accurate assessment of
liver fibrosis has become increasingly important as it
allows for individualized management. The lack of accu-
rate, reproducible and easily applied methods for assess-
ment of hepatic fibrosis has been the major limitation
for both the clinical management and research in liver
diseases.
The following paragraphs summarize the current
modalities used for quantifying and staging hepatic
fibrosis (Figure 1).
Liver biopsy scoring techniques
For the past 50 years liver biopsy has been considered to
be the gold standard for staging of liver fibrosis. This
technique allows physicians to obtain diagnostic infor-
mation not only on fibrosis, but also on many other
liver injuring processes, such as inflammation, necrosis,
steatosis, hepatic deposits of iron or copper. However,
many recent studies clearly highlight several crucial
drawbacks of liver biopsy, including variable accessibil-
ity, high cost, sampling errors and inaccuracy due to
inter- and intra-observer variability of pathologic inter-
pretations [19]. In addition, there is a small but impor-
tant risk of liver biopsy-associated morbidity and
mortality, with pain and hypotension as the most fre-
quent complications and intraperitoneal bleeding and
injury to the biliary system as the most serious compli-
cations. Studies reveal that the risk for hospitalization
after liver biopsy is 1-5%, the risk for severe complica-
tions is 0.57%, and mortality rates vary from 0.009% to
0.12% [20,21]. Because of these reasons, some patients
may opt to forgo liver biopsy and may not know the
stage of their liver disease with important prognostic
implications.
The history of the fibrosis scoring systems dates back
to 1981 when the histological features of chronic hepati-
tis were evaluated for potential importance in determin-
ing its prognosis by Knodell and colleagues [22]. The
Ishak score, or revised Knodell system, has primarily
been applied to chronic hepatitis B and C. It considers
grading and staging as two separate items; liver fibrosis
is classified as: 0 = absent, 1-2 = mild, 3-4 = moderate
and 5-6 = severe/cirrhosis. The first three axes of Kno-
dell HAI (Histologic Activity Index) relate to the
necroinflammatory grade of the disease while the fourth
f e a t u r ea s s e s s e st h es t a g eo ft h ed i s e a s eb ye v a l u a t i n g
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tal-portal linking, portal-central fibrous bridges, and the
formation of fibrous septa and parenchymal nodules
[23]. This grading system has been subsequently modi-
fied by other pathologists [24,25]. There are some lim-
itations of HAI index, in particular, related to the
interobserver variation [26]. Another limitation of the
Ishak/Knodell fibrosis score is its nonlinearity as it
includes scores 0, 1, 3, and 4.
The Metavir scoring system was designed specifically
for patients with hepatitis C using a sum of experience-
based opinions of 10 pathologists augmented by subse-
quent stepwise discriminant analysis [27]. The scoring
uses both grading and staging systems as it includes two
separate scores, one for necroinflammatory grade (A for
activity) and another for the stage of fibrosis (F). The
grade is a number based on the degree of inflammation,
which is usually scored from 0-4, with A0 being no
activity and A3 to A4 considered severe activity. Deter-
mining the amount of inflammation is important
because it can correlate with hepatic fibrosis. The degree
of activity is assessed by the integration of the severity
of both (periportal) necrosis and lobular necrosis as
described in a simple algorithm [28]. The fibrosis score
(F) is defined as: F0 = no scarring, F1 = portal fibrosis
without septa, F2 = portal fibrosis with rare septa, F3 =
numerous septa without cirrhosis and F4 = cirrhosis or
advanced scarring of the liver [29]. The intra- and inter-
observer variability of Metavir seems to be improved
[30]. The main advantage of the Metavir score for hepa-
titis C is its relative simplicity, its focus on necroinflam-
matory lesions, and its increased sensitivity in the
fibrosis score due to the addition of one extra fibrosis
evaluating level.
However, the limitations of the Knodell score also apply
to the Metavir score as it retains the semi quantitative and
Staging 
of fibrosis
Indirect 
Biomarkers
Direct 
Biomarkers
Combinational 
panels
Proteomics 
profiles Liver Biopsy 
Liver imaging
Figure 1 A scheme depicting various means of liver fibrosis diagnostics. Liver biopsy is an invasive method that remains an imperfect
golden standard. Proteomics based profiles are unlikely to be introduced to routine clinical care anytime soon, but are valuable from the
research point of view. Imaging techniques, serum biomarkers and biomarker panels are advancing along the route to the clinic stage, but
require extensive validation.
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biopsy scoring systems often varies among different
pathology laboratories, which makes score comparisons
among patients from different centers rather difficult.
Built-in sampling error problems associated with accepted
scoring systems requires the need to design studies with
extremely large sample sizes [31].
In addition to staging hepatic fibrosis for viral hepati-
tis, three pathologic criteria have been used for patients
with NAFLD. Of these, the original classification of
NAFLD subtypes was developed to histologically cate-
gorize NAFLD into 4 subtypes): type 1 NAFLD = steato-
sis alone; type 2 NAFLD = steatosis with lobular
inflammation only; type 3 NAFLD = steatosis with hepa-
tocellular ballooning; or type 4 NAFLD = steatosis with
Malloy-Denk bodies or fibrosis. According to these cri-
teria, types 3 and 4 NAFLD were considered to be
NASH. Subsequently, Brunt’s criteria was developed to
grade NASH and used for clinical research in patients
with NAFLD. According to Brunt’s criteria, liver biopsy
with at least fat and lobular inflammation is graded as
mild (grade 1), moderate (grade 2) or marked (grade 3)
NASH. More recently, the NAFLD Activity Score (NAS)
was developed to provide a numerical score for patients
who most likely have NASH. Accordingly, NAS is the
sum of the separate scores for steatosis (0-3), hepatocel-
lular ballooning (0-2), lobular inflammation (0-3), with
most patients with NASH having a NAS score of ≥5.
Fibrosis, according to both Brunt and NAS, is scored
from 0 to 4 (grade 0 = none; 1 = centrilobular/perisinu-
soidal; 2 = centrilobular plus periportal; 3 = bridging; 4
= cirrhosis) [32]. These pathologic protocols for NAFLD
suffer from a lack of data assessing their inter-observer
variability as well as their inability to predict liver-
related mortality.
To overcome the previously mentioned complications
posed by liver biopsy, alternative non-invasive methods
for quantifying and staging liver fibrosis have been
developed. These methods range from serum biomarker
assays to advanced imaging techniques (Figure 1 and
Table 1).
It is important to note that the performance of each
non-invasive method, serum- or instrument based, is
evaluated against a properly scored liver biopsy that
continues to serve as an imperfect but indispensable
standard for comparative studies of liver fibrosis diag-
nostics. Every non-invasive test is evaluated using the
area under the ROC curve (AUC) that combines the
sensitivity and specificity of a given quantitative marker
for the diagnosis of a specific definition of fibrosis. For
each test, sensitivity and specificity are usually assessed
by enumerating correct diagnoses of advanced fibrosis
(i.e., stages F2, F3, and F4 in the METAVIR scoring sys-
tem) versus minimal or non-advanced fibrosis (i.e.,
stages F0, F1). Recently, the prevalence of each of the
fibrosis stages, considered advanced or non-advanced
fibrosis, in study cohorts was found to be highly asso-
ciated with the AUC estimates [33]. Strikingly, AUCs
for a typical study were shown to fluctuate in a range
from 0.67 to 0.98 for the same test and the same type of
liver disease depending on the distribution of stages
within the cohort [33]. This means that AUCs obtained
in different studies should not be compared directly, but
a unifying correction for the stage distribution should
be performed first.
Obviously, this fact reflectso nt h ec o n c l u s i o n st h a t
can be made by comparison of the AUC-evaluated per-
formances of non-invasive tests. Moreover, it is impor-
tant to bear in mind that the biopsy itself has an AUC,
which could be derived from the “true gold standard”
studies of entire section of the liver [34]. Due to liver
biopsy sampling variability, the discrimination of the
adjacent fibrosis stages by METAVIR scoring on typical
15-mm core is correct in approximately 65% of cases,
reflecting in AUC of only 0.82 when compared with the
entire liver [34]. Therefore, the performances of non-
invasive biomarkers with AUCs comparable to liver
biopsy’ own AUC are difficult to compare and verify. In
the absence of studies involving whole liver sectioning,
some of the proposed candidate biomarker may, in fact,
reflect the overall fibrosis within the liver better than
the liver biopsy itself.
T h er a t eo fa d o p t i o no fn o n - i n v a s i v ed i a g n o s t i c sf o r
liver fibrosis differs from country to country, but
remains limited. At present, the use of non-invasive pro-
cedures could be recommended as pre-screening tools,
which may allow physicians to narrow down the
patients’ population before definitive testing of liver
fibrosis by biopsy of the liver (Figure 2).
Imaging Techniques
The activation of HSCs and deposition of the ECM
leads to alterations in liver microstructure that are
reflected by an increase in the liver stiffness and changes
in the blood flow. Recent radiological advances allow the
bedside assessment of liver stiffness with techniques like
Fibroscan, ARFI and MRI.
Transient Ultrasound Elastography (FibroScan)
An ultrasound-based technology for quantitatively asses-
sing hepatic stiffness has been introduced in the last
several years both in Europe and other parts of the
world and is consistently gaining traction. FibroScan
measures the stiffness (or elasticity) of the hepatic par-
enchyma using both ultrasound (5 MHz) and low-fre-
quency (50 Hz) elastic waves produced by a specialized
ultrasound vibrator applied to the body wall and
coupled with 1D ultrasound imaging that measures the
p r o p a g a t i o ns p e e do faw a v eu s i n gap u l s e - e c h o
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Page 5 of 15Table 1 Serum biomarkers and imaging techniques for the detection of liver fibrosis: A summary of the features
Feature Serum biomarkers Imaging techniques
Invasiveness Minimal (venopuction) None
Sensitivity to sampling error Minimal Some
Interpretability of the test High, if instructions are closely followed Depends on experience of operator
Costs per test Depend on a type of the test, but generally
comparable with tests for serum insulin
Depends on the cost of equipment: highest for MRI. lowest for ARFI
Limitations imposed by
anthropometric features
None For TE and ARFI: width of the inter-costal space, the presence of ascites,
the body mass index of patient and presence of visceral adiposity
For MRI: fitting within the magnetic bore, severe hemochromatosis,
claustrophobia
Possibility of multiplexing Possible, but often hard to implement Not applicable
Suitability for longitudinal
monitoring
High High
Accuracy for the prediction
of cirrhosis
Moderate-to-High High
Accuracy for the prediction
of adjacent stages of fibrosis
Low-to-Moderate Low-to-Moderate
Interference by
necroinflammatory activity
and steatosis
Variable depending on the type of the test Detectable for TE and ARFI
Any HCV/HBV 
patient with 
current infection, 
once a year
Patients 
with BMI > 30, 
normal AST and ALT, 
once a three years
Non-obese patients 
with AST or ALT 
within upper 20% of ULN 
or above ULN 
once a year
Patients with 
daily drinking 
habit, 
every two years 
Non-invasive screening 
by biomarkers, community health clinic
Significant fibrosis ruled out  Significant fibrosis ruled in 
Non-invasive screening 
by imaging method, hepatologist office 
Significant fibrosis ruled in 
using independent non-invasive method
Liver Biopsy at the hospital
Figure 2 Decision tree that may help to guide the cost-effective diagnosis of liver fibrosis in large populations of prospective
patients.
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Page 6 of 15ultrasound. Since fibrotic tissue is harder than healthy
liver tissue, the shear wave measurement provides
immediate quantitative assessment of the “degree of
stiffness” which takes less than 5 minutes to collect.
Most of the FibroScan studies originate in Europe where
this method was invented and approved for use in rou-
tine clinical settings. FibroScan was reported to be of
value in the diagnosis of the fibrosis accompanying var-
ious liver diseases including hepatitis B and C, alcoholic
liver disease, and non alcoholic fatty liver disease
(NAFLD) [35,36]. By meta-analysis, FibroScan is consid-
ered to be a reliable method for the diagnosis of signifi-
cant fibrosis (AUC = 0.84), severe fibrosis (0.89), and
cirrhosis (0.94) [36]. However, for the diagnosis of sig-
nificant fibrosis, there was a high variation of the AUCs
dependent on the underlying liver disease [36]. In a
recent multicenter prospective study, FIBROSTIC,
FibroScan measurements predicted cirrhosis with higher
AUROCs (0.89 - 0.90) than serum based biomarkers
(AUROC 0.77-0.86) [37].
Similar to serum-based tests, transient elastography
can be repeated over time, thus, providing an opportu-
nity for longitudinal disease monitoring and comparative
assessments that are difficult when the primary diagnos-
tic means is a liver biopsy. FibroScan technology is not
free of limitations. Most importantly, its accuracy in
predicting significant cirrhosis is influenced by necroin-
flammatory activity and steatosis common in patients
with NAFLD [38]. To improve the performance of
FibroScan, its combinationw i t hs e r u mb a s e dF i b r o M -
eter test was suggested [39]. According to large series of
liver stiffness measurements that included 13,369 indivi-
dual examinations, these measures remain impossible to
interpret in nearly one in five cases [40]. The success
rate of the procedure is dependent on observer expertise
as well as on age of the patient, the width of the inter-
costal space, the presence of ascites, the body mass
index of patient and presence of visceral adiposity
[40,41]. Accordingly, the diagnostic performance of tran-
sient ultrasound elastography is much lower in patients
with early-stage hepatic fibrosis, increased fatty infiltra-
tion of the liver on biopsy, or high body mass index
(≥28 kg/m
2) [42].
Acoustic radiation force impulse (ARFI)
ARFI imaging combines conventional unltrasonography
of the liver with evaluation of local liver stiffness. As
regions of evaluation can be chosen using ultrasound,
ARFI allows operator avoidance of anatomical obstacles,
e.g. large blood vessels [43,44]. In a small study of 99
patients with liver disease and 23 healthy controls, ARFI
measurements were highly correlated to that of FibsroS-
can, but the rate of invalid measurements with ARFI
was lower (P < 0.04). Importantly, in contrast to FibroS-
can, liver steatosis had no statistical influence on ARFI
results [45]. Other studies compared ARFI to Forns’
index and other non-invasive, clinical parameters-based
diagnostic tests, and found that in hepatitis C patients
ARFI’ diagnostic ability was superior to any of these
[46]. An important advantage of ARFI is that it can be
performed with software integrated into conventional
ultrasound equipment as opposed to purchasing expen-
sive TE-enabling Fibroscan units.
Magnetic Resonance Imaging (MRI)
MRI technology can be used to measure both liver stiff-
ness and characteristic water-diffusion abnormalities
associated with cirrhosis [47]. It should not be confused
with magnetic resonance spectroscopy (MRS), which
provides images of the metabolic abnormalities in sub-
jects with liver disease.
Several types of enhanced MRI have been developed
to evaluate the degree of liver fibrosis. One such modifi-
cation, Magnetic Resonance Elastography (MRE) directly
visualizes and quantitatively measures acoustic shear
waves progressing through the liver tissue. MRE involves
a three-step process:1) generating mechanical waves
within the tissues of interest; 2) imaging the micron
level displacements caused by propagating waves using a
special MRI technique with oscillating motion-sensitiz-
ing gradients; and 3) proces s i n gt h ew a v ei m a g e su s i n g
an inversion algorithm to generate quantitative maps of
the physical properties of the liver [48]. Importantly,
MRI accurately reflects the distribution of the fibrous
material in the liver, thus, at least in some cases helping
with identification of the nature of injury [8].
The current evidence support the observation that a
normal mean liver stiffness value by MRE in the setting
of chronic liver disease is consistent with stage 0 fibrosis
on liver biopsy [48], while fibrosis of stages 1-4 are also
diagnosed accurately [48-50]. In a study encompassing
50 patients with biopsy-proven liver disease and 35
healthy volunteers, receiver operating characteristic
(ROC) analysis showed that, with a shear stiffness cutoff
value of 2.93 kPa, the predicted sensitivity and specificity
for detecting liver fibrosis were 98% and 99%; respec-
tively [49]. Notably, stage I fibrosis detection was possi-
ble; while the detection of hepatic fibrosis with stages 2
or more, the area under the ROC curve (AUC) was 0.96
[50]. It was also noted that the technical success rate for
MRE is significantly higher than that of transient elasto-
graphy (94% vs. 84%). The only practical limitation of
performing MR elastography in very obese patients is
that the patient has to fit within the magnetic bore, the
diameter of which is also further reduced by the pre-
sence of the transducer.
It is important to note that MRE is associated with
substantially higher costs than FibroScan or ARFI.
Furthermore, MRE use can be limited for claustrophobic
patients or those with severe hemochromatosis. These
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acceptance and its primary purpose remains a research.
Serum Biomarkers of Fibrosis
In recent years, interest in identifying and describing
liver fibrosis by using non invasive surrogate markers
has been on the rise. Serum markers of liver fibrosis
offer an attractive, cost effective alternative to liver
biopsy for both patients and clinicians. In addition to
being substantially less invasive, there are practically no
complications, little or no sampling errors and small
observer related variability. Moreover, measurements
may be performed repeatedly, thus, allowing for a
dynamic monitoring of fibrosis [51].
A majority of commonly used biomarkers were identi-
fied in the past two decades in relatively low-throughput
clinical studies centered on the pathogenic mechanisms.
Recently, the process of biomarker discovery was aug-
mented by a number of commercial high-throughput
pipelines aimed at singling out the molecules differen-
tially expressed between various physiological and
pathological states followed by validation of their perfor-
mance in independent cohorts and true translation from
bench to bedside as pre-packaged diagnostic kits.
While the first step on this path, the discovery of new
biomarker leads, produced a variety of promising candi-
dates, assessing each biomarker in a statistically signifi-
cant number of samples and controls still constitutes a
major technical challenge. Another problem is the fair
assessment of relative value of novel biomarkers or bio-
marker panels as compared to existing non-invasive pre-
dictors. Typically, the performance of each novel
biomarker is compared to that of either one or more
other panels, and the assessment is limited to one
pathological condition (i.e. alcoholic liver disease). Given
this approach, the exact contribution of each newly
described biomarker to the prediction of liver fibrosis is
difficult to evaluate. A recent study of Park and coau-
thors specifically addressed this question and concluded
that the simultaneous addition of several biomarkers
adds only modestly to clinical predictive factors for the
risk assessment of individual patients [52].
The Ideal Biomarker of Liver Fibrosis
The diagnostic value of serum markers of liver fibrosis
has been investigated in numerous studies. Based on
clinical and research needs, the ideal marker for liver
fibrosis would have the following characteristics:
￿ Be highly sensitive and specific to identify different
stages of fibrosis
￿ Be readily available, safe, inexpensive and
reproducible
￿ Be applicable to the monitoring of disease progres-
sion or regression as apart of natural history of liver dis-
ease or treatment regimens
￿ Not be susceptible to false positive results, for exam-
ple, in individuals with inflammation related to other
diseases
Although no single ideal marker exists, several mar-
kers have been identified as possible useful indicators of
fibrosis when used in conjunction with each other.
Biomarkers of fibrosis are commonly divided into
Direct and Indirect markers. Direct markers are frag-
ments of the liver matrix components produced by
hepatic stellate cells (HSC) during the process of ECM
remodeling. Indirect markers include molecules released
into the blood due to liver inflammation, molecules
synthesized/regulated or excreted by the liver, and mar-
kers of processes commonly disrupted due to liver func-
tion impairment, such as insulin resistance (Table 2 and
[53]). Direct and indirect markers may be used alone or
- more commonly - in combination with each other, to
produce composite scores. The calculation of such
scores can be relatively simple or can be based on com-
plicated formulas (e.g. those underlying Fibrotest/
Fibrosure).
T h em o s tc o m m o n l yu s e dm a r k e r sa r ed i s c u s s e di n
details below.
Direct Biomarkers
Procollagen type I carboxy terminal peptide (PICP)
and Procollagen type III amino-terminal peptide
(PIIINP) In the healthy human liver the most abundant
collagens are the fibril-forming types I and III. In its
mature form, the collagen is integrated into the ECM.
During fibrogenesis, type I collagen levels increase up to
eightfold. Additionally, the ratio of the type I/III also
changes from 1:1 in the healthy liver to 1:2 in the cir-
rhotic liver [54].
PIIINP is another major constituent of the connective
tissue. Its relative concentration in the basement mem-
brane is higher in hepatic fibrogenesis and is closely fol-
lowed by an increase in its serum level [55]. In acute
hepatitis, levels of serum PIIINP correlate with amino-
transferase levels. In chronic liver disease, serum PIIINP
reflects the stage of liver fibrosis [56]. Unfortunately,
PIIINP is not specific for the fibrosis of the liver as it is
also elevated in acromegaly, lung fibrosis, chronic pan-
creatitis, and rheumatologic disease [54].
PICP levels are normal in patients with mild chronic
hepatitis C and elevated in 50% of patients with moder-
ately advanced or advanced chronic hepatitis C, includ-
ing patients with liver cirrhosis of this etiology [57].
However, there is no correlation between the levels of
PICP and PIIINP.
Metalloproteinases (MMPs) MMPs form a family of
structurally related proteolytic enzymes that mediate the
degradation of the ECM and the basal membranes
[56,58]. The three most commonly studied human
metalloproteinases are MMP-2 (gelatinase-A), MMP-3
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secreted by activated HSCs; elevated levels of MMP-2
and its proenzyme have been observed in various liver
diseases [59]. During hepatic fibrogenesis, the expression
of MMP-2 is markedly increased. The potential for
MMP-2 for predicting liver fibrosis remains unclear as
some contradictory data have been reported by studies
performed so far [60,61]. In contrast to MMP-2, MMP-
9 levels show their value primarily in the diagnosis of
hepatocellular carcinoma [62]. In one of the studies,
MMP-9 levels were negatively correlated to the histolo-
gical severity of the liver disease in patients with chronic
hepatitis C [63].
Tissue inhibitors of matrix metalloproteinases
(TIMPs) TIMPs are secreted proteins that interact with
MMPs and modulate their activation and functioning.
TIMP-1 controls activity of most MMPs, whereas
TIMP-2 specifically inhibits MMP-2. TIMPs-dependent
inhibition of ECM degradation may promote liver fibro-
sis; elevation of TIMPs’ levels has been observed in
chronic liver disease. For example, chronic hepatitis C
causes the elevation of both TIMP-1 and TIMP-2 in
corollary with fibrosis progression [60]. A recent study
of the relationship between serum MMP-9, TIMP-1 and
fibrosis in 50 patients with various chronic liver disease
showed that serum levels of MMP-9 in chronic hepatitis
patients were low as compared to the controls (P <
0.05) [63]. Moreover, serum MMP-9 levels decrease as
chronic hepatitis progresses to cirrhosis, while TIMP-1
levels increase along with an increase of the degree of
fibrosis (r = 0.73, P < 0.001). These findings prompt
using serum TIMP-1 as a non-invasive assay in liver
fibrosis [63].
Transforming growth factor-b1( T G F - b1) is a pleiotro-
pic cytokine involved in tissue growth, differentiation,
ECM production and the immune response. Three iso-
forms (b1, b2a n db3) of this cytokine have been identi-
fied, but only TGF-b1 is linked to liver fibrogenesis.
TGF- b1 is also commonly accepted as a central compo-
nent of fibrogenic response to wounding and is up-regu-
lated in a variety of different diseases [8,54]. A
correlation between TGF- b1 levels and the rate of
fibrosis progression is widely accepted [41,64].
Hyaluronic acid (HA) is a glycosaminoglycan compo-
nent of the ECM that is synthesized by the HSC. In a
study of NAFLD-related fibrosis of the liver, HA was
found to be the best class I biomarker of fibrosis, being
associated with an area under curve (AUC) of 0.97 [65].
Since the negative predictive value of HA is much
higher (98-100%) than its positive predictive value
(61%), its main utility in its ability to rule out advanced
fibrosis and cirrhosis [54].
YKL-40 (chondrex) is a mammalian homologue of the
bacterial chitinases involved in remodeling or degrada-
tion of the extracellular matrix [66]. In liver diseases,
serum levels of YKL-40 are closely related to the degree
of histologically documented fibrosis [67].
Laminin is a major non-collagenous glycoprotein
synthesized by the HSC and deposited in the basement
membrane of the liver. During fibrosis, laminin accumu-
lates around the vessels, in the perisinusoidal spaces and
near the portal tract [68]. Elevated levels of laminin and
pepsin resistant laminin (laminin P1) were found to cor-
relate with the degree of perisinusoidal fibrosis [69].
Connective tissue growth factor (CTGF) is synthesized
in response to profibrogenic factor TGF-b by both
Table 2 Indirect Serum Markers of Liver Fibrosis
Indices Individual components Sensitivity (%) Specificity (%)
AST/ALT ratio Aspartate aminotransferase,
Alanine aminotransferase
53 100
PGA Protrombin index, GGT, apolipoprotein A1 91 81
APRI AST/platelet count 89 75
FibroSpect II HA, TIMP-1, a2-macroglobulin 83.5 66.7
FibroTest/FibroSure g2 macroglobulin, g2 globulin, g globulin, apolipoprotein A1, GGT, total bilirubin 75 85
FibroIndex Platelet count, AST, GGT 78 74
FibroMeter Platelet count, g2 macroglobulin, AST, age, prothrombin index, HA, blood urea nitrogen 81 84
Forns Age, platelet count, GGT, cholestered levels 94 51
Hepascore Age, gender, bilirubin, GGT, HA, g2-macroglobulin 63 89
FIB-4 Platelet count, ALT, AST, platelet count, age 70 74
SHASTA Index HA, AST, albumin 100 52
Simple test age, hyperglycemia, BMI, platelet count, albumin, AST/ALT 78 58
OELF/ELF age, HA, N-terminal propeptide of type III collagen, TIMP-1 90 41
GGT: g glutamyl transferase, HA: hyaluronic acid, TIMP-1: Tissue inhibitors of matrix metalloproteinase- 1, ALT: Alanine aminotransferase, AST: Aspartate
aminotransferase
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CTGF levels decrease in the end-stage cirrhosis [70].
Paraoxonase 1 (PON-1) is an enzyme that hydrolyzes
lipid peroxides, has antioxidant properties and influ-
ences hepatic cell apoptosis. Measurement of serum
PON1 activity has been proposed as a potential test for
the evaluation of liver function, however, it clinical
acceptance is limited due to instability and toxicity of its
substrate, paraoxon [71]. Ferre ant coauthors [72]
showed that baseline and stimulated PON1 activities are
decreased in chronic hepatitis and in liver cirrhosis. The
combination of baseline serum PON1 with five standard
biochemical tests had higher classification accuracy (94%
of patients; 96% of controls) than the five standard tests
alone (75% of patients; 96% of controls). ROC analysis
showed that AUROC for chronic hepatitis was 0.89 and
was 0.96 for cirrhosis, both compared to controls [72].
Microfibril-associated glycoprotein 4 (MFAP-4) is a
ligand for integrins. In a recent study, quantitative ana-
lysis of MFAP-4 serum levels showed high diagnostic
accuracy for the prediction of non diseased liver versus
cirrhosis (AUROC = 0.97, P < 0.0001) as well as stage 0
versus stage 4 fibrosis (AUROC = 0.84, P < 0.0001), and
stages 0 to 3 versus stage 4 fibrosis (AUROC = 0.76, P <
0.0001) [73]
Limitations of Direct serum biomarkers of fibrosis
￿ They reflect the rate of matrix turnover (not only
deposition) and have a tendency to be more elevated
when associated with high inflammatory activity. As a
consequence, extensive matrix deposition might not be
detected in the presence of minimal inflammation;
￿ They are not liver-specific and their serum levels
may be elevated in the presence of concomitant sites of
inflammation;
￿ Serum levels of markers depend on their clearance
rates, which are influenced by the dysfunction of
endothelial cells, impaired biliary excretion or renal
function [53].
Indirect Biomarkers of Fibrosis
Most Indirect biomarkers of fibrosis are integrated with
one or more fibrosis predicting biomarker panels.
AST/ALT ratio
Aspartate aminotransferase (AST) and Alanine amino-
transferase (ALT) are hepatic enzymes that are released
into the bloodstream from damaged hepatocytes. The
predictive value of the AST/ALT ratio has been vali-
dated in non-alcoholic liver disease, chronic viral hepati-
tis, primary sclerosing cholangitis, and primary biliary
cirrhosis [74]. In many forms of acute and chronic liver
injury or steatosis (fatty infiltration of the liver), this
ratio is less than or equal to 1, while in alcoholic hepati-
tis, an AST/ALT ratio is often greater than 2. While
these ratios are suggestive of certain etiology of liver
conditions, there is too much overlap between groups to
rely on AST/ALT exclusively when making a diagnosis -
for example, in patients with both hepatitis C and his-
tory of alcohol abuse [75].
The PGA index combines the measurement of the
Prothrombin Index, g glutamyl transferase levels and
apolipoprotein A1. It was subsequently modified to the
PGAA index by the addition of a2- macroglobulin,
which resulted in marginal if any improvement in its
performance. In chronic liver diseases, the PGA index
has a relationship to both the inflammation and the
fibrosis (P< 0.01, P< 0.05 respectively). However, overall
accuracy of this index is relatively low [76,77].
The AST-to-Platelet Ratio Index (APRI) is calculated
as (AST/upper limit of normal range)/platelet count
(10
9/L) × 100. This index has previously been validated
as a surrogate marker of significant hepatic fibrosis in
HIV/HCV-coinfected patients, and has recently been
used to determine advanced fibrosis in HIV-monoin-
fected patients [78]. However, recent large meta-analysis
suggested that APRI can identify hepatitis C-related
fibrosis with only a moderate degree of accuracy [79].
The Forns index is based on 4 routine clinical vari-
ables: age, platelet count, cholesterol levels, and g gluta-
myl transferase. This method can be used to
differentiate patients with mild (F0-F1) fibrosis from
those with severe (F2-F4) fibrosis, but it is less accurate
in distinguishing patients with grades F2 versus F4. The
Forns index has been validated in other cohorts as a
predictive tool for response to anti-HCV therapy [80].
The HepaScore combines age, gender, bilirubin, g glu-
tamyl transferase, hyaluronic acid, and g2-macroglobulin
into a score from 0.00 to 1.00 [81]. In 512 chronic HCV
patients, automated HepaScores showed good predictive
performances for significant fibrosis (AUROC = 0.81),
severe fibrosis (AUROC = 0.82), and cirrhosis (AUROC
= 0.88). Importantly, HepaScore test can be automated
using a single analyzer [81].
The FIB-4 score which combines platelet count, ALT,
AST and age, was originally developed for use in HIV-
HCV co-infection. Use of this index correctly classified
87% of patients with FIB-4 values outside 1.45-3.25 and
avoided biopsy in 71% of the validation set with an
AUROC of 0.765, sensitivity of 70% and a specificity of
97% for differentiating Ishak 0-3 from 4-6 [82]. This
model was subsequently validated by Vallet-Pichard in a
large cohort of HCV mono-infected patients, with the
finding that using these ranges, 78% of 847 biopsies
were correctly classified [AUROC 0.85 for severe fibrosis
and 0.91 for cirrhosis] [83].
The SHASTA Index which consists of serum hyaluro-
nic acid (HA), AST, and albumin was evaluated in a
cohort of 95 patients with HIV/HCV co-infection [84].
Using a cut off of 0.8 resulted in a specificity of 100%
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to less than 5% of patients. At the other end of the spec-
trum, a cutoff of less than 0.30 was associated with a
sensitivity of more than 88% and a negative predictive
value of more than 94%. Overall 42% of patients could
be correctly classified at either extreme; however 58%
were classifiable with scores between 0.3 and 0.8. How-
ever, the SHASTA index in HIV/HCV in this cohort has
performed significantly better than the APRI test [85].
The
13C-methacetin breath test (MBT) is amongst sev-
eral
13C breath tests used for the quantitative non-inva-
sive assessment of cytochrome P450-dependent
hepatocellular function [86]. MBT is rapidly metabolized
by healthy liver cells into acetaminophen and
13CO2 in
a single dealkylation event, so the increase of
13CO2 in
breath samples can be quantified by isotope ratio mass
spectrometry or non dispersive isotope-selective infrared
spectroscopy [86]. MBT has been shown to have high
sensitivity (92.6%) and specificity (84.1%) in predicting
liver cirrhosis. The areas under the curve were found to
be 0.958 for predicting cirrhosis and 0.827 for identify-
ing patients with advanced fibrosis [87]. MBT does not
involve a blood test and can provide an immediate
result at the point-of-care.
The FIBROSpect II test uses a combination of compo-
nents in the fibrogenic cascade, such as hyaluronic acid,
TIMP-1 (tissue inhibitor of metalloproteinase), and a-2-
macroglobulin to calculate a composite score. The test
is intended to differentiate mild fibrosis (Metavir stages
F0 to F1) from more severe disease (Metavir stages F2
to F4), and had been shown to do well in chronic hepa-
titis C cohorts [88,89].
The FibroTest and FibroSure are identical tests mar-
keted under different names in Europe and America for
the assessment of fibrosis and necroinflammatory activ-
ity. The FibroTest score is computed by accessing a pro-
prietary website and entering the patient’sa g e ,s e x ,a n d
results for serum haptoglobin, a2-macroglobulin, apoli-
poprotein A1, g-glutamyltransferase, and bilirubin ana-
lyses [90]. It generates a score that is correlated with the
degree of liver damage in people with a variety of liver
diseases. Due to the variability of component of assays
and analyzers, FibroTest assays can only be performed
in validated laboratories [91]. A recent study showed an
AUROC of 0.69 and 0.91 for the diagnosis of significant
fibrosis (F≥2) and liver cirrhosis in 74 patients compris-
ing of 36 with HCV, 10 with HBV, and 28 with primary
biliary cirrhosis [92]. The sensitivity and specificity
values for FibroTest based detection of primary severe
fibrosis were found to be 75% and 85%, respectively
[77].
The FibroIndex was developed by Koda and co-
authors [92] for liver fibrosis in chronic hepatitis C.
This test relies on platelet count, AST and serum IgG.
FibroIndex showed high predictive values for significant
fibrosis, including in a subgroup of HCV cases with nor-
mal alanine aminotrasferase (NALT) [93]. The sensitiv-
ity and specificity of FibroIndex for detecting fibrosis in
patients with HCV were 78% and 74% [94]. In a com-
parative study, the validated AUROC of the FibroIndex
for predicting significant fibrosis was found to be 0.83
and 0.82, which is better than those of the Forns index
and APRI in patients with chronic hepatitis C [94].
The FibroMeter is a combination of the platelet count,
prothrombin index, AST, g2 macroglobulin, hyaluronate,
blood urea nitrogen and age. The good performance
and applicability of FibroMeter was validated in a num-
ber of chronic liver diseases, including chronic viral
hepatitis B or C, alcoholic liver disease (ALD) and non-
alcoholic fatty liver disease (NAFLD). An important fea-
ture of the FibroMeter is that it presents the amount of
liver fibrosis as a percentage of fibrous tissue within the
liver. Another significant feature of FibroMeter is that it
validates the results through an expert system that
detects erroneous results. FibroMeter has two main
diagnostic targets - fibrosis stage corresponding to the
histological staging system Metavir and the amount of
fibrosis which corresponds to morphometric determina-
tions of the fibrotic area [95].
Two additional panels have been developed to assess
hepatic fibrosis specifically in NAFLD. First, the so
called “Simple Test” for fibrosis in NAFLD is a relatively
easy to use panel that includes age, hyperglycemia, body
mass index, platelet count, albumin, and AST/ALT [96].
When the purpose of performing a liver biopsy in
NAFLD is to determine the extent of hepatic fibrosis,
using the Simple Test can correctly stage 90% of
patients, obviating the need for liver biopsy in approxi-
mately 75% of patients. In addition to the “Simple Test”,
another panel for hepatic fibrosis is the Original Eur-
opean Liver Fibrosis (OELF) panel [97], which includes
age, hyaluronic acid, amino-terminal propeptide of type
III collagen, and tissue inhibitor of matrix metalloprotei-
nase 1. A simplified version OELF is ELF, which does
not include age, and seems to perform well in patients
with NAFLD [98]. The performances of ELF and OELF
were found to be almost identical. In a recent study,
when the ELF panel was used for “ruling in” severe
fibrosis, only 14% of NAFLD patients in this cohort
required a liver biopsy. The combination of Simple/ELF
panel reached an AUROC of 0.98 for distinguishing
severe fibrosis from initial stages of the fibrotic disease
in patients with NAFLD [98].
The Proteomics based tests assess patterns of protein
or glycoprotein by mass spectroscopy using serum sam-
ples. Importantly, while a series of ‘peaks’ generated, the
precise identities of these peaks remain unknown. For
example, Callewaert N et al., 2004 developed tests based
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(GlycoCirrhoTest and GlycoFibroTest) [99], which could
be both cost-effective and could rapidly determine a sig-
nature profile for n-glycans. At first, it was reported that
the combination of GlycoCirrhoTest with the FibroTest
produced a sensitivity of 79% and specificity of 86% in
distinguishing cirrhosis from non cirrhotic disease.
However, later tests showed limited applicability of the
test to discern the etiology of liver diseases. Specifically,
under galactosylation did not show a significantly differ-
ent quantitative alteration in the cirrhotic and noncir-
rhotic population of all etiologies [100]. Moreover, the
same modifications seem to continuously reappear in all
liver diseases: hyperfucosylation, increased branching
and a bisecting N-acetylglucosamine [100]. Larger pro-
spective studies are necessary to determine the clinical
application of these new technologies.
The recently developed Phosphoproteomics tests serve
the goal of improving and understanding the patho-
genesis of liver fibrosis to more than actually contri-
buting to the practicality of clinical diagnostics. For
example, phosphoproteomics based tests predict the
fibrosis of the liver have been used to profile the phos-
phorylated (i.e. activated) forms of the major signaling
proteins in visceral adipose samples of patients with
NAFLD [101].
Recently, a number of attempts were made to improve
sensitivity and specificity of non-invasive biomarker-
based tests through combining them using sequential
algorithms. One example of such studies is a work of
Sebastiani et al, who combined APRI, Forns’ index and
Fibrotest to reduce need for liver biopsy in hepatitis C
patients by 50-70% [102]. Later, the same group of
authors combined APRI with FibroTest-FibroSure and
validated this approach known as SAFE (sequential algo-
rithm for fibrosis evaluation) biopsy in a very large
cohort of hepatitis C patients (N = 2035) [103]. For the
detection of fibrosis, SAFE biopsy had remarkable accu-
racy of 92.5% (95% confidence interval, 0.89-0.94),
obviating the need for 81.5% of liver biopsies [103].
Conclusions
Successful individualized management of chronic liver
disease depends on the correct staging of liver fibrosis.
In order to provide the means of monitoring the course
of liver disease and its response to therapy, staging
should be performed in a non-invasive and reproducible
manner. The fact that the process of fibrogenesis is a
component of the normal healing response hampers the
development of disease-specific biomarkers; this is why
t h eq u e s tf o rs u i t a b l en o n - i n v a s i v eb i o m a r k e ro fl i v e r
fibrosis has become one of the biggest challenges in
translational hepatology. A number of non-invasive
techniques ranging from serum biomarker assays to
advanced imaging techniques are being developed.
Among non-invasive methods that have gained the
strongest clinical foothold are FibroScan elastometry
and serum-based APRI and FibroTest. There are many
other tests that are not yet widely validated, but remain
promising. Major validation efforts to enroll large
cohorts of patients with chronic liver diseases controlled
for important confounders such as ethnicity, body mass
index and etiology of liver disease, must be undertaken.
Importantly, most non-invasive tests fail to differenti-
ate between early stages of fibrosis. In fact, most of
these tests can primarily distinguish cirrhosis from no
or minimal fibrosis. For the diagnosis of significant liver
fibrosis (F > or = 2) non invasive tests cannot yet
replace liver biopsy. Therefore, the current utility of
non-invasive diagnostics remains limited to pre-screen-
ing allowing physician to narrow the population of
patient before definitive testing of liver fibrosis by biopsy
of the liver.
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